4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Inhibrx Biosciences, Inc. (INBX) operates in the Biotechnology industry and is headquartered in La Jolla, United States with about 109 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, INBX reported $1M in revenue and ($140M) in net income.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
Interactive charts & full statements → Open the INBX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $1M | $0M | $2M | $1M |
| Operating Income (EBIT) | ($135M) | ($331M) | ($219M) | ($115M) |
| Net Income | ($140M) | $1.7B | ($241M) | ($115M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $1M | $0M | — |
| Operating Income (EBIT) | ($31M) | ($31M) | ($34M) | ($27M) | ($43M) | — |
| Net Income | ($33M) | ($33M) | ($35M) | ($29M) | ($43M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $146M | $181M | $308M | $17M |
| Total Liabilities | $138M | $47M | $264M | $24M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive INBX viewer.
About TickerBase · Data methodology & sources